Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients

R. H. Wiesner, B. J. Steffen, K. M. David, A. H. Chu, R. D. Gordon, J. R. Lake

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described. To investigate the risk of LAR (rejection ≥6 months post-transplantation) data from the Scientific Registry of Transplant Recipients (SRTR) were used. We studied adult primary liver transplant recipients transplanted between June 1, 1995, and April 30, 2004, with hepatitis C virus (HCV) (n = 3356), hepatitis B virus (HBV) (n = 550) or a nonviral (n = 5740) primary cause of liver disease who were recorded as receiving continuous 3-(MMF + Tacro + steroids) versus 2-drug (Tacro + steroids) therapy for at least 6 months immediately post transplantation. Kaplan-Meier analysis showed significantly lower LAR rates 4 years post-transplant in 3- versus 2-drug HCV, HBV and nonviral disease patients. Multivariate regression confirmed 3- versus 2-drug therapy to be associated with a decreased risk of LAR. Late graft survival was significantly lower at 4 years post-transplant for patients with LAR 6-12 months post-transplantation versus patients with early rejection (78.0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes.

Original languageEnglish (US)
Pages (from-to)1609-1616
Number of pages8
JournalAmerican Journal of Transplantation
Issue number7
StatePublished - Jul 2006


  • Graft survival
  • Late acute rejection
  • Long-term outcomes
  • Patient survival


Dive into the research topics of 'Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients'. Together they form a unique fingerprint.

Cite this